Guideline for Gradual Citalopram Discontinuation

Rationale for Gradual Taper

Abrupt cessation or standard 2–4 week tapers result in withdrawal symptoms in up to 44 % of patients, whereas a gradual reduction markedly lowers this risk. 1
Citalopram discontinuation syndrome commonly includes dizziness, muscle tension, chills (each ~44 %), anxiety/irritability and amnesia (each ~28 %), plus paresthesias, “electric shock” sensations, gastrointestinal upset, insomnia, and balance problems. 1
Compared with paroxetine, fluvoxamine, and sertraline, citalopram carries a lower overall risk of discontinuation syndrome, but clinically significant symptoms still occur frequently. 1

Reduce the current dose by 10 % of the current dose every 2–4 weeks (e.g., 40 mg → 36 mg → 32.4 mg, etc.). 1
When the dose becomes low, slow the taper further; some patients require 5 % or smaller decrements to avoid abrupt receptor‑occupancy drops. 1
Continue tapering to doses well below the minimum therapeutic level (far under 10 mg) before complete cessation. 1
Example schedule: start at 40 mg, reduce to 36 mg for 2–4 weeks, then to 32.4 mg, then to 29.2 mg, and so on; at 10 mg reduce to 9 mg, then 8.1 mg, continuing the same pattern. 1

Monitor patients closely during the first 1–2 weeks after each dose reduction to detect emergent withdrawal symptoms. [2][1]
If symptoms are intolerable, resume the most recent tolerated dose and then decrease more gradually, extending the interval between reductions to 3–4 weeks or longer. 1
Distinguish withdrawal from relapse: withdrawal has a sudden onset after a dose change, whereas true relapse develops gradually. 1

Do not use alternate‑day dosing or skip doses during tapering, as this creates fluctuating receptor occupancy and increases withdrawal risk. 3
Do not stop at the minimum therapeutic dose (10 mg) and then discontinue; continue tapering to very low doses (e.g., 2–3 mg or less) before final cessation. 1

For pediatric and adolescent patients, parental or caregiver oversight during dose changes is essential to ensure safety and adherence. 1
Routine addition of benzodiazepines or other sedatives is discouraged because they introduce additional withdrawal risks. 4

Inform patients that most withdrawal symptoms are temporary and do not signify treatment failure or relapse. 1
Advise patients to report severe agitation, confusion, rapid heart rate, muscle rigidity, fever, or suicidal thoughts promptly, as these may indicate serotonin syndrome or worsening depression. 3